These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 28826084)

  • 21. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.
    Davis DW; Takamori R; Raut CP; Xiong HQ; Herbst RS; Stadler WM; Heymach JV; Demetri GD; Rashid A; Shen Y; Wen S; Abbruzzese JL; McConkey DJ
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):678-89. PubMed ID: 15701856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis, and biological activities of novel hexahydropyrazino[1,2-a]indole derivatives as potent inhibitors of apoptosis (IAP) proteins antagonists with improved membrane permeability across MDR1 expressing cells.
    Shiokawa Z; Hashimoto K; Saito B; Oguro Y; Sumi H; Yabuki M; Yoshimatsu M; Kosugi Y; Debori Y; Morishita N; Dougan DR; Snell GP; Yoshida S; Ishikawa T
    Bioorg Med Chem; 2013 Dec; 21(24):7938-54. PubMed ID: 24169315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis, and evaluation of 3,5-disubstituted 7-azaindoles as Trk inhibitors with anticancer and antiangiogenic activities.
    Hong S; Kim J; Seo JH; Jung KH; Hong SS; Hong S
    J Med Chem; 2012 Jun; 55(11):5337-49. PubMed ID: 22575050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and anti-hepatitis C virus activity of novel ethyl 1H-indole-3-carboxylates in vitro.
    Sellitto G; Faruolo A; de Caprariis P; Altamura S; Paonessa G; Ciliberto G
    Bioorg Med Chem; 2010 Aug; 18(16):6143-8. PubMed ID: 20638289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and biological evaluation of 2-indolinone derivatives as potential antitumor agents.
    Zou H; Zhang L; Ouyang J; Giulianotti MA; Yu Y
    Eur J Med Chem; 2011 Dec; 46(12):5970-7. PubMed ID: 22019188
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of benzo[g]indol-3-carboxylates as potent inhibitors of microsomal prostaglandin E(2) synthase-1.
    Koeberle A; Haberl EM; Rossi A; Pergola C; Dehm F; Northoff H; Troschuetz R; Sautebin L; Werz O
    Bioorg Med Chem; 2009 Dec; 17(23):7924-32. PubMed ID: 19884011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
    Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
    Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2.
    Salerno S; Marini AM; Fornaciari G; Simorini F; La Motta C; Taliani S; Sartini S; Da Settimo F; García-Argáez AN; Gia O; Cosconati S; Novellino E; D'Ocon P; Fioravanti A; Orlandi P; Bocci G; Dalla Via L
    Eur J Med Chem; 2015 Oct; 103():29-43. PubMed ID: 26318056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and evaluation of tumor cell growth inhibition of methyl 3-amino-6-[(hetero)arylethynyl]thieno[3,2-b]pyridine-2-carboxylates. Structure-activity relationships, effects on the cell cycle and apoptosis.
    Queiroz MJ; Calhelha RC; Vale-Silva LA; Pinto E; Almeida GM; Vasconcelos MH
    Eur J Med Chem; 2011 Jan; 46(1):236-40. PubMed ID: 21138784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
    Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
    J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase.
    Sun L; Liang C; Shirazian S; Zhou Y; Miller T; Cui J; Fukuda JY; Chu JY; Nematalla A; Wang X; Chen H; Sistla A; Luu TC; Tang F; Wei J; Tang C
    J Med Chem; 2003 Mar; 46(7):1116-9. PubMed ID: 12646019
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents.
    Zhang X; Raghavan S; Ihnat M; Hamel E; Zammiello C; Bastian A; Mooberry SL; Gangjee A
    Bioorg Med Chem; 2015 May; 23(10):2408-23. PubMed ID: 25882519
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CPU-12, a novel synthesized oxazolo[5,4-d]pyrimidine derivative, showed superior anti-angiogenic activity.
    Liu J; Deng YH; Yang L; Chen Y; Lawali M; Sun LP; Liu Y
    J Pharmacol Sci; 2015 Sep; 129(1):9-17. PubMed ID: 26154846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis, and evaluation of indolinones as inhibitors of the transforming growth factor β receptor I (TGFβRI).
    Roth GJ; Heckel A; Brandl T; Grauert M; Hoerer S; Kley JT; Schnapp G; Baum P; Mennerich D; Schnapp A; Park JE
    J Med Chem; 2010 Oct; 53(20):7287-95. PubMed ID: 20919678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and structure-activity relationships of boswellic acid derivatives as potent VEGFR-2 inhibitors.
    Shen S; Xu X; Liu Z; Liu J; Hu L
    Bioorg Med Chem; 2015 May; 23(9):1982-93. PubMed ID: 25819335
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.
    Roberts WG; Whalen PM; Soderstrom E; Moraski G; Lyssikatos JP; Wang HF; Cooper B; Baker DA; Savage D; Dalvie D; Atherton JA; Ralston S; Szewc R; Kath JC; Lin J; Soderstrom C; Tkalcevic G; Cohen BD; Pollack V; Barth W; Hungerford W; Ung E
    Cancer Res; 2005 Feb; 65(3):957-66. PubMed ID: 15705896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
    Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
    Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined inhibition of vascular endothelial growth factor and platelet-derived growth factor signaling: effects on the angiogenesis, microcirculation, and growth of orthotopic malignant gliomas.
    Farhadi MR; Capelle HH; Erber R; Ullrich A; Vajkoczy P
    J Neurosurg; 2005 Feb; 102(2):363-70. PubMed ID: 15739567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders.
    Cross NC; Reiter A
    Acta Haematol; 2008; 119(4):199-206. PubMed ID: 18566537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 3. Evaluation of 5-amino-linked thiazolo[5,4-d]pyrimidine and thiazolo[5,4-b]pyridine derivatives.
    Hirose M; Okaniwa M; Miyazaki T; Imada T; Ohashi T; Tanaka Y; Arita T; Yabuki M; Kawamoto T; Tsutsumi S; Sumita A; Takagi T; Sang BC; Yano J; Aertgeerts K; Yoshida S; Ishikawa T
    Bioorg Med Chem; 2012 Sep; 20(18):5600-15. PubMed ID: 22883026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.